Sangamo Therapeutics stock analysis
Sangamo Therapeutics (0R1D) Share Price & Analysis
0R1D Stock Chart & Stats
- Day’s Range
- $0.11 - $0.11
- 52-Week Range
- $0.03 - $0.60
- Previous Close
- $0.11
- Volume
- N/A
- Average Volume (3M)
- 28.85K
- Market Cap
- $45.57M
- Enterprise Value
- $87.94M
- Total Cash (Recent Filing)
- $27.59M
- Total Debt (Recent Filing)
- $19.33M
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margin
The high gross margin indicates that Sangamo’s underlying programs can generate substantial contribution after direct costs if revenue scales. Although operating expenses currently overwhelm this benefit, maintaining strong program-level margins could support improved economics if development assets or partnerships produce recurring revenue.
Asset Monetization
The completed ST-920 transaction converts a major clinical asset into immediate cash and preserves potential milestone proceeds. This demonstrates that Sangamo’s pipeline retains strategic value to larger biotechnology companies and may provide resources for restructuring and stakeholder recovery.
Genomic Medicine And Partnerships
Sangamo operates in genomic medicine, an area with potential to address serious neurological and hematologic diseases through gene regulation and editing. Its collaboration model can provide partner resources, development expertise, and milestone or royalty opportunities beyond internally funded commercialization.
Bears Say
Chapter 11 And Delisting
Chapter 11 and the Nasdaq delisting place Sangamo under court supervision and materially weaken the position of common shareholders. The restructuring creates uncertainty around asset allocation, recoveries, and future ownership, while OTC trading may not reflect eventual shareholder value.
Persistent Cash Burn
Persistent operating and free-cash-flow deficits show that the business has not funded its activities internally. Continued cash consumption increases dependence on asset sales, financing, or partner support, limiting strategic flexibility and making sustained operations more difficult without restructuring.
Declining Revenue And Large Losses
Revenue is declining while operating and net losses remain very large, indicating that the current cost base is far above the company’s revenue run-rate. This weak earnings profile reduces the ability to reinvest organically, increases funding pressure, and undermines near-term business sustainability.
0R1D FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
What is Sangamo Therapeutics’s market cap?
When is Sangamo Therapeutics’s upcoming earnings report date?
How were Sangamo Therapeutics’s earnings last quarter?
Is Sangamo Therapeutics overvalued?
Does Sangamo Therapeutics pay dividends?
What is Sangamo Therapeutics’s EPS estimate?
How many shares outstanding does Sangamo Therapeutics have?
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sangamo Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Sangamo Therapeutics Stock Smart Score
Company Description
Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander D. Macrae
- Employees
- 142
- Website
- www.sangamo.com
- Address
- 501 Canal Blvd, Richmond, CA, 94804, US
Sangamo Therapeutics (0R1D) Earnings & Revenues
0R1D Earnings Call
Earnings Call SentimentNeutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.
View all GB:0R1D earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 14 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |
